jeffrey krasner is president of emerging biocommunications, which consults to early- and mid-stage life science companies.
.
.following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
later, after robert and other family members said their final goodbyes, hospital workers started wheeling helen out of the room.
.
© 2018 southern california public radio